Platelet Function Inhibitors Targeting Gαs to Limit Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiplatelet therapies fail to adequately address thrombotic disorders such as myocardial infarction and stroke while minimizing the risk of bleeding, and are limited in treating immune-related platelet disorders like immune thrombocytopenia.
Innovation Solution
Development of compounds with Formula (I) or their pharmaceutically acceptable salts, which inhibit platelet activation and aggregation by targeting the Gαs signaling pathway, thereby inhibiting thrombus formation without disrupting hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiplatelet therapies (aspirin and P2Y12 receptor antagonists) are used to prevent thrombotic events, then morbidity and mortality from thrombosis are decreased, but the risk of bleeding increases and the therapies are limited in treating immune-related platelet disorders
Solution Approach 1:
The patent changes the molecular target parameter from traditional COX-1 or P2Y12 receptors to the Gαs signaling pathway. This parameter change enables selective inhibition of platelet activation without the broad effects of conventional therapies, thereby reducing bleeding risk while maintaining thrombosis prevention efficacy.
Solution Approach 2:
The patent introduces Gαs as an intermediary signaling molecule in the platelet activation pathway. By targeting Gαs instead of direct platelet receptors, the therapy achieves more precise control over platelet function, inhibiting thrombus formation while preserving hemostasis and reducing bleeding complications.
2Reliability
If current antiplatelet therapies are used to prevent thrombosis, then thrombotic events are reduced, but the therapies cannot adequately treat immune-related platelet disorders like immune thrombocytopenia
Solution Approach 1:
The patent achieves universality by targeting the Gαs signaling pathway, which is centrally involved in platelet activation regardless of the underlying cause. This single target approach enables the therapy to effectively treat both thrombotic disorders and immune-related platelet disorders, expanding the treatment scope beyond conventional therapies.
Solution Approach 2:
The patent segments the platelet activation pathway into distinct components, identifying Gαs as a critical node that can be selectively inhibited. This segmentation allows the therapy to address different pathophysiological mechanisms (thrombosis vs. immune-mediated platelet destruction) through a common target, thereby treating diverse conditions with a single agent.
3Object-generated harmful factors
If traditional antiplatelet therapies are used to inhibit platelet activation, then platelet aggregation is reduced, but primary hemostasis is disrupted and bleeding risk increases
Solution Approach 1:
The patent applies local quality by achieving selective inhibition of platelet activation through Gαs targeting. This localized approach specifically blocks thrombus formation pathways while preserving normal hemostatic function, thereby maintaining primary hemostasis and reducing bleeding risk compared to non-selective antiplatelet therapies.
Data Source
AI summary
Disclosed herein are small molecule inhibitors of platelet function, and methods of using the small molecules to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof:wherein the substituents are as described.